Replay available

BioLineRX (TASE:BLRX) Q4 2020 Earnings Call

BioLineRX (TASE:BLRX) Q4 2020 earnings call, held 2021-02-23. Watch the replay and read the transcript on 6ix.

Tue, February 23, 2021 at 10:00 AMendedReplay
BioLineRX (TASE:BLRX) Q4 2020 Earnings Call
Company
BioLineRX Ltd. (TASE:BLRX)
Period
Q4 2020 earnings call
Date
Tue, Feb 23, 2021, 10:00 AM ET
Replay
Watch the replay on this page · 21 min

On 6ix: 6ix.com/event/biolinerx-ltd-blrx-q4-2020-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx fourth quarter and full year 2020 results conference call. All participants are present in a listen-only mode. Following the management's formal presentation, instructions will be given for the question and answer session. For operator assistance during the conference, please press star zero. I would now like to turn over the call and Timothy McCarthy of LifeSci Advisors to read the Saints Harbor Statement. Tim, please go ahead.

0:33 Thank you, Operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call, other than historical facts, are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project, and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition and other operating results. These include, but are not limited to, the risk factors and other qualifications contained in BioLineRx's annual report on Form 20F Quarterly reports filed in the 6K and other reports filed by BioLineRx with the SEC to which your attention is directed.

1:26 Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. BioLineRx expressly disclaims any intent or obligation to update these forward-looking statements. At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.

1:48 Thank you, Tim, and good morning, everyone. And thank you for joining us on our fourth quarter earnings conference call today. Earlier this morning, we issued our Q4 results press release, a copy of which is available in the investor relations section of our website. It was also filed as a 6K. As is our custom, I will begin with some brief prepared remarks, and then Mali Zeevi, our chief financial officer, will provide a short discussion of our financial results. We will then open up the call to your questions. also joining the call for Q&A are Abby Weinstein, our Chief Medical Officer, and Ella Sorani, our Chief Development Officer. The fourth quarter 2020 was our most significant yet as we produced positive data sets from two key programs, stem cell mobilization and metastatic pancreatic cancer, or PDAC. I would like to begin with a brief discussion of stem cell mobilization.

2:39 In October, we announced positive results from pre-planned interim analysis of our Genesis Phase 3 study evaluating our lead clinical candidate, Motixifortide, in stem cell mobilization for patients undergoing autologous hematopoietic stem cell transplantation. Stem cell mobilization is an area of significant unmet need, as 50-70% of patients are poor mobilizers, necessitating multiple apheresis sessions. In addition, a portion of these patients require 1-4 daily injections of Mozabil on top of GCSF. and the rest of the team. were overwhelmingly positive, as the interim analysis found highly statistically significant evidence for the primary endpoint favoring treatment with Mutaxifortide.

3:48 Upon the recommendation of the Independent Data Monitoring Committee, study recruitment was terminated early at 122 out of a planned 177 patients. We are planning to announce top-line data in early Q2 of this year, including full primary and secondary efficacy endpoints. These data are exciting for two very important reasons. First, we hope that the data will show that the combination of metixifortide and GCSF is well positioned to become the new standard of care in autologous stem cell transplantation. And second, stem cell mobilization is our most expedient path to registration. It goes without saying that if metixifortide is ultimately approved for this indication, it would be a transformational event for our company.

4:33 To that end, we are already proceeding with all activities in support of an NDA submission in this indication, which we are targeting for the first half of 2022, including a pre-NDA meeting with the FDA in the second half of this year. Now turning to our PDAC program. In December, we announced final results from the Phase 2A Combat Keynote 202 study of latixifortide in combination with Merck's PD-1 inhibitor, Contruda, and chemotherapy as a second-line therapy in stage 4 metastatic PDEC. A total of 43 patients initially diagnosed with unresectable stage 4 metastatic PDEC who had progressed following first-line gemcitabine-based therapy were enrolled in the triple combination arm. Patients received motixifortide monotherapy priming treatment for five days.

5:22 Mali Zeevi, Ella Sorani, John Lacey, Philip Serlin Many patients are first diagnosed with advanced stage 4 disease due mainly to the fact that this cancer is asymptomatic while it is metastasizing. And as mentioned, the patients in our combat keynote study were initially diagnosed at stage 4, so this was a patient population with an extremely poor prognosis, and perhaps worse than the patient populations evaluated in previous PDAC studies to date.

6:13 It is against this backdrop that the data that we announced in December are all the more encouraging. The data demonstrated substantial improvement across all study endpoints as compared to historical data, including overall survival, median progression-free survival, confirmed overall response rate, and disease control rate. This is a big differentiation factor from other studies in this indication, which showed improvement in only one specific endpoint. Let's recap the results. Median overall survival in months was 6.5 months in our combat keynote study versus 4.7 months of historical data. Median progression-free survival was 4.0 months in our combat keynote study versus 2.7 to 3.1 months of historical data. Our confirmed overall response rate in the combat keynote study was 13.2% versus 7.7% in the historical data.

7:07 Our overall response rate was 21.2% versus 16% relating to historical data. And finally, our disease control rate in this study was 63.2% versus between 30 and 50% relating to historical data. As you can see, again, the data demonstrated a substantial improvement across all study endpoints. We refer you to our press release dated December 16th for more detail, as well as important references to accompany the historical data. We are currently planning the next development steps for this program, including discussions with potential collaboration partners and development of a protocol for a randomized control study. At this point, I'd like to very briefly recap two investigator-initiated trials that are also evaluating Otixifortide.

7:57 Also in PDAC, Columbia University is leading a Phase II study evaluating motixifortide in combination with the anti-PD-1 simiplimab known by its brand name, Liptio, and standard of care chemotherapy, gemcitabine and napaclitaxel. Notably, this is an entirely new study that is evaluating this combination as a first-line treatment as compared to the combat study, which is second-line. This investigator-initiated Phase II study will initially enroll 10 to 12 PDAC patients. and will be expanded to a total of 40 patients following an evaluation of the initial 10 to 12 patients based on predefined criteria. Data from this study is anticipated in mid-2022, although since this trial is not a company-sponsored trial, the timelines are ultimately driven by the independent investigators and therefore could be subject to change.

8:49 A second investigator-initiated trial of metixoporotide is ongoing in patients with COVID-induced acute respiratory distress syndrome, or ARDS. The open-label single-arm Phase 1B study is being conducted at Wolfson Medical Center in Holon, Israel, and will enroll up to 25 hospitalized COVID patients. An interim analysis is planned after 10 patients have completed the initial treatment period, after which a decision to continue or not will be conducted. These preliminary results could be announced as early as the second half of this year, or Although as with the Columbia University study, the timelines are driven by the independent investigators and could be subject to change. Regarding our second clinical candidate, AGI-134, recall that we are evaluating safety and tolerability at the recommended dose in multiple solid tumor types in a Phase I-IIA study. The study is designed to evaluate a wide array of biomarkers and to validate AGI-134's mechanism of action. We will also assess clinical and pharmacodynamic parameters. In September 2019, we announced positive safety data, and later that same month, we moved quickly to initiate Part 2, which is the dose expansion phase. We previously talked about enrollment delays caused by COVID-19, particularly as the pandemic impacted the UK and Israel particularly hard.

10:10 And while this has caused delays, enrollment has now resumed and new sites and countries have been added and we remain on track to report data in the back half of this year. This is unchanged from the guidance that was provided last quarter. I would now like to turn the call over to Mali Zeevi, our CFO, who will give a brief overview of our key fourth quarter financial statement items. Mali, please go ahead.

10:34 Thank you, Phil. In our financial discussion, we will only go over a few significant items on this call. Research and Development Expenses, and Cash. Therefore, let me invite you to review the filings we made this morning, which contain our financials, operating and financial review, and press release for additional information. Research and Development Expenses for the year ended December 31, 2020, were $18.2 million, a decrease of $5.2 million, and compared to $23.4 million for the comparable period in 2019. The decrease resulted primarily from termination of the battle clinical study for Motixifortide in 2019, from lower expenses associated with the Motixifortide combat clinical trial, and from lower expenses associated with the AGI-134 study, as well as a decrease in share-based compensation and payroll Due to a company-wide salary reduction related to the COVID-19 pandemic.

11:40 Turning to cash, the company held $22.6 million of cash, cash equivalents, and short-term bank deposits as of December 31, 2020. Subsequent to year-end, we completed a financing that raised gross proceeds of $34.5 million and received another $9.8 million in gross proceeds from the exercise of Outstanding Warrants. And with that, I'll turn the call back over to Phil.

12:10 Thank you, Mali. In closing, as is our custom, I would like to take a few moments to summarize our key upcoming data milestones. First, final results from the Genesis Phase III study in stem cell mobilization in early Q2 of this year. Second, data from the Phase I-IIa study of AGI134 in multiple solid tumor types in the second half of this year. also a pre-NDA meeting with the FDA for stem cell mobilization in the second half of this year, and finally, an NDA submission for stem cell mobilization in the first half of 2022. In summary, we have achieved two very significant milestones during the fourth quarter with positive results of our genesis and combat keynote studies, suggesting that motixifortide is proving to be a versatile molecule capable of enhancing standards of care in multiple cancer types. We are pleased with our continued progress, particularly in light of the disruptions caused by the pandemic, and I look forward to providing future updates.

13:12 With that, we have now concluded the formal part of our presentation. Operator, we will now open up the call to questions. Thank you. Ladies and gentlemen, at this time we will begin the question and answer session. If you would like to ask a question, please press star 1. To withdraw your question, please press star 2. If you are using speaker equipment, kindly lift the headset before pressing the numbers. Your questions will be polled in the order they are received. Please stand by while we poll for your questions. The first question is from Jason McCarthy of Maxim Group. Please go ahead.

13:58 Hi everyone, it's Dave on the line for Jason. Thanks for taking my questions. So regarding the Phase 2 study in PDAC, can you shed some color on how the toxicity profile of the combination treatment being evaluated compares to the current standard of care and do you plan on meeting regulators in any other regions globally with regards to potential commercialization? Thanks.

14:22 Okay, Abby, you want to take the first part of that question about the toxicity?

14:25 Yes, sure. What we have seen is that the combination of motixofortide and chemotherapy and Keytruda has less toxicity in some of the parameters, like neutropenia and infection, and this is based on the mechanism of action of BL-8040. And in the other parameters, we didn't see any increase in the signs, meaning that this combination is safe as given each one of the drugs Separately. I hope this answers your question.

15:00 That was the first part. The second part was whether we're considering having any discussions with regulatory authorities in the syndication. Am I correct? Yeah, yeah, in other regions, like in the European Union, for example. Are you talking about in PDAC or are you talking about in stem cell mobilization? Well, for both, just for Letitia's forechild.

15:23 Okay, yeah, so, you know, so, yeah, so, I mean, right now, we're focusing, you know, you know, we're laser-focused on moving forward in the U.S. and meeting with the FDA, having the pre-NDA meeting, and then doing the NDA submission. We are, of course, contemplating... Discussing and moving forward with registering and speaking with the authorities in Europe, for example, but that's going to be at the next stage. Right now, as a small company, we feel that it's imperative for us to move forward as quickly as possible to get the drug approved in the U.S. As far as the other indications, PDAC, that's something that we are considering doing some kind of end of Phase II meeting or Type C meeting, but right now, I think we're, again, laser focused on trying to develop the clinical protocol for the next study and having numerous discussions with parties that may be collaboration partners with us on the next study.

16:30 Great. Thanks for the additional clarity. I appreciate it. No problem. Have a great day. The next question is from Joe Pantagenese from HC Weinreich. Please go ahead.

16:45 Hey everybody, thanks for taking the question and hope you're all doing well. So a couple questions, you answered one of them already, but I guess maybe what would be a bit of your wish list for this randomized control study in PDAC? Do you think there might be an interim look that could allow you for accelerated approval ahead of finishing the entire study? because of the unmet need?

17:10 We think that's a possibility. It's not clear to us. We may consider, again, a lot depends on the collaboration partner that we end up working with. It may be a phase two, three study with an interim analysis. It might be just a large phase two study. It's hard to say right now. I think it's something that we're probably trying to put together A couple of possibilities. Of course, since this is an unmet medical need, depending on the data, the robustness of the data, there is the possibility of getting conditional approval, but right now I think that right now we're focusing on building the protocol and then we'll have to bring the data and see how it happens.

17:59 No, that's great. Thanks. And then sticking with Matixa Forsythe, obviously, you know, you're really having a corporate shift over the next year as you look towards an NDA, as you put it, as you said, for next year. So can you describe a little bit of what I guess I would portray as very important behind-the-scenes activity in preparing for that NDA, and what do you think are some of the major outstanding things that you have right now and where you stand on manufacturing? Ella, you want to take that?

18:30 Yes, sure. Okay. So, yes, of course, you know, the entire CMC package has to be submitted to FDA. We are currently not just the CMC. All the, you know, NDA supporting activities with regards to the preclinical CMC, clinical pharmacology, the entire package has to be put together and prepared in a way expected by FDA in order to be able to submit it.

19:05 And to your question about the drug product, it's part of the NSA, part of the NDA submission, and of course we are preparing for that as well.

19:14 Yeah, of course, including the validation batches and everything else that are required. Yeah, so I mean, it's a, you know, I think, as I'm sure you're aware, it's a huge project, and we're putting, you know, we're putting massive efforts On this, as I said, we're laser focused to move this forward as quickly as possible.

19:33 Great. Thanks a lot, guys. Appreciate it. If there are any additional questions, simply press star 1. To withdraw your question, press star 2. Please stand by while we poll for your questions. There are no further questions at this time. Before I ask Mr. Phil Serlin to go ahead with his closing statement, I would like to remind participants that a replay of this call is scheduled to begin two hours after the conference. In the U.S., please call 1-888-782-4291. In Israel, please call 03-925-5904. Internationally, please call 972-3255.

20:26 925-5904. Mr. Serlin, would you like to make your concluding statement?

20:34 Yes, I would. Thank you. This concludes our call this morning. I'd like to thank you again for your interest in BioLineRx at this critical and transformative time for our company, and we look forward to our next comprehensive update in May. Be safe and have a great day. Thank you very much for your time. Thank you. This concludes the BioLineRx fourth quarter and full year 2020 conference call. Thank you for your participation. You may go ahead and disconnect.

Follow BioLineRX Ltd. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Timothy McCarthy

LifeSci Advisors

Phil Serlin

Chief Executive Officer

Mali Zeevi

Chief Financial Officer

Abby Weinstein

Chief Medical Officer

Ella Sorani

Chief Development Officer

Joe Pantagenese

Analyst, HC Wainwright

More from BioLineRX Ltd.